AIMS: To evaluate the feasibility of lesion related treatment strategies in patients treated for severe carotid artery disease with angioplasty and stenting (CAS) under embolic protection devices (EPD). METHODS AND RESULTS: From December 2001 to August 2004 a total of 377 consecutive patients were enrolled to undergo CAS. The procedure was conducted by using several types of stents (cobalt-alloy frame, nitinol frame) and of EPD (filter-wires, proximal endovascular clamping devices) applied to specific lesions and/or anatomies.Primary endpoint was to assess the death and stroke rate at discharge.Secondary endpoints were to test the feasibility and safety of tailored CAS (angiographic success, any -complication between discharge and 30 days, death of any cause at 30 days).The procedural success was achieved in 377/377 patients (100%).Adverse events included:1. during procedure: 2 TIAs (0.53%)2. at discharge: 1 death procedure related (0.27%), 1 major stroke (0.27%), 2 minor strokes (0.53%), 4 TIAs (1.06%), 1 intracranial hemorrhage (0.27%); all adverse event rate at discharge 2.92%; all strokes and death rate at discharge 1.06%;3. at 30 day f.u.: one death not procedure related (0.27%), 1 minor stroke (0.27%);4. overall procedure related stroke and death rate: 1.33%. CONCLUSIONS: Our data suggest that using new materials/devices matched to specific lesions or anatomies is safe and effective.
AIMS: To evaluate the feasibility of lesion related treatment strategies in patients treated for severe carotid artery disease with angioplasty and stenting (CAS) under embolic protection devices (EPD). METHODS AND RESULTS: From December 2001 to August 2004 a total of 377 consecutive patients were enrolled to undergo CAS. The procedure was conducted by using several types of stents (cobalt-alloy frame, nitinol frame) and of EPD (filter-wires, proximal endovascular clamping devices) applied to specific lesions and/or anatomies.Primary endpoint was to assess the death and stroke rate at discharge.Secondary endpoints were to test the feasibility and safety of tailored CAS (angiographic success, any -complication between discharge and 30 days, death of any cause at 30 days).The procedural success was achieved in 377/377 patients (100%).Adverse events included:1. during procedure: 2 TIAs (0.53%)2. at discharge: 1 death procedure related (0.27%), 1 major stroke (0.27%), 2 minor strokes (0.53%), 4 TIAs (1.06%), 1 intracranial hemorrhage (0.27%); all adverse event rate at discharge 2.92%; all strokes and death rate at discharge 1.06%;3. at 30 day f.u.: one death not procedure related (0.27%), 1 minor stroke (0.27%);4. overall procedure related stroke and death rate: 1.33%. CONCLUSIONS: Our data suggest that using new materials/devices matched to specific lesions or anatomies is safe and effective.
Authors: T Okazaki; S Sakamoto; K Shinagawa; N Ichinose; D Ishii; T Matsushige; Y Kiura; K Kurisu Journal: Eur Radiol Date: 2018-07-19 Impact factor: 5.315
Authors: D Stojanov; M Ilic; P Bosnjakovic; M Zivkovic; S Jolic; N Vukasinovic; A Ignjatovic; B Ilic; D Benedeto-Stojanov Journal: AJNR Am J Neuroradiol Date: 2011-12-22 Impact factor: 3.825
Authors: G Simonetti; R Gandini; F Versaci; E Pampana; S Fabiano; M Stefanini; A Spinelli; C A Reale; M Di Primio; E Gaspari Journal: Radiol Med Date: 2008-09-26 Impact factor: 3.469
Authors: Alex Szólics; László K Sztriha; Péter Szikra; Miklós Szólics; András Palkó; Erika Vörös Journal: Eur Radiol Date: 2009-12-22 Impact factor: 5.315
Authors: Piotr Pieniążek; Przemysław Nowakowski; Krzysztof Ziaja; Adam Kobayashi; Wojciech Uchto; Jakub Sulżenko; Roman Machnik; Łukasz Tekieli; Dariusz Stańczyk; Krzysztof Plens; Wojciech Zasada; Artur Dziewierz; Damian Ziaja Journal: Postepy Kardiol Interwencyjnej Date: 2019-12-31 Impact factor: 1.426